« PreviousNext »The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1210-1216, December 2009
Volume 124, Issue 6 , Pages 1210-1216, December 2009
Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma
Full Text Available
Supported by Novartis Pharma AG.
Disclosure of potential conflict of interest: B. Lanier has served as a consultant for Alcon Laboratories and has received research support from Alcon Laboratories, Genentech/Novartis, and AstraZeneca. T. Bridges has served on the speakers' bureau and has received research support from Novartis and Genentech. The rest of the authors have declared that they have no conflict of interest.
ClinicalTrials.gov Identifier: NCT00079937
PII: S0091-6749(09)01409-2
doi:10.1016/j.jaci.2009.09.021
© 2009 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
« PreviousNext »The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1210-1216, December 2009
Volume 124, Issue 6 , Pages 1210-1216, December 2009

